IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk

Cancer Discov. 2022 Jul 6;12(7):1615-1616. doi: 10.1158/2159-8290.CD-22-0472.

Abstract

In this issue, Hu and colleagues unveil that IFNα administration combined with anti-PD-1 therapy can potentiate murine and human CD8+ T-cell antitumor response in hepatocellular carcinoma, highlighting a novel therapeutic strategy for hepatocellular carcinoma. See related article by Hu et al., p. 1718 (6) .

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular* / drug therapy
  • Glucose
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Liver Neoplasms* / drug therapy
  • Mice
  • Tumor Microenvironment

Substances

  • Immune Checkpoint Inhibitors
  • Glucose